Published by Alexander Bueso on 22nd June 2022
(Sharecast News) - Analysts at Citi reiterated their 'buy' recommendation for shares of AstraZeneca following the release of the results of the DESTINY-Breast 04 clinical trial using its Enhertu treatment against metastatic breast cancer.
URL: http://www.digitallook.com/dl/news/story/32766888/...